34564-85-7

Upstream product

• 591-18-4 1-Bromo-3-iodobenzene 
• 32117-52-5 1-(1-(4-methoxyphenyl)ethylidene)-2-tosylhydrazine 
• 54118-76-2 (3-bromophenyl)(4-methoxyphenyl)methanone 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 1183275-88-8 C₁₅H₁₅BrO₂ 

Downstream Products

• 1398519-65-7 C₁₆H₁₃BrINO₂ 
• 1180017-26-8 (RS)-4-(5'-chloro-2'-fluoro-biphenyl-3-yl)-4-(4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 1180017-10-0 (RS)-4-(3'-chloro-biphenyl-3-yl)-4-(4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 1180017-06-4 C₂₁H₁₉N₃O₂ 
• 1180017-28-0 C₂₀H₁₈N₄O₂ 
• 1180017-04-2 C₂₁H₁₈FN₃O₂ 
• 1180017-16-6 (RS)-4-[3-(2-Fluoro-pyridin-3-yl)-phenyl]-4-(4-methoxy-phenyl)-4,5-dihydro-oxazol-2-yl-amine 
• 1180015-27-3 (RS)-4-(3-bromo-phenyl)-4-(4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine 

Relevant academic research and scientific papers

Palladium-Catalyzed One-Pot Reaction of Hydrazones, Dihaloarenes, and Organoboron Reagents: Synthesis and Cytotoxic Activity of 1,1-Diarylethylene Derivatives

A new three-component assembly reaction between N-tosylhydrazones, dihalogenated arenes, and boronic acids or boronate esters was developed, producing highly substituted 1,1-diarylethylenes in good yields. The two C-C bonds formed through this coupling ha

Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and cns penetrable BACE inhibitors for the treatment of alzheimers disease

A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human β-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound 11a resulted in a significant reduction of CNS Aβ40 in naive rats.

4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES

The present invention relates to a compounds of formula I wherein R1, R1′, R2, R3, R4, X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.